BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36763517)

  • 21. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family.
    Steinle A; Li P; Morris DL; Groh V; Lanier LL; Strong RK; Spies T
    Immunogenetics; 2001; 53(4):279-87. PubMed ID: 11491531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein.
    Wu J; Chalupny NJ; Manley TJ; Riddell SR; Cosman D; Spies T
    J Immunol; 2003 Apr; 170(8):4196-200. PubMed ID: 12682252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
    Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D
    Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms.
    Bilotta MT; Abruzzese MP; Molfetta R; Scarno G; Fionda C; Zingoni A; Soriani A; Garofalo T; Petrucci MT; Ricciardi MR; Paolini R; Santoni A; Cippitelli M
    FASEB J; 2019 Aug; 33(8):9489-9504. PubMed ID: 31125275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells.
    Kato N; Tanaka J; Sugita J; Toubai T; Miura Y; Ibata M; Syono Y; Ota S; Kondo T; Asaka M; Imamura M
    Leukemia; 2007 Oct; 21(10):2103-8. PubMed ID: 17625602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure of the HCMV UL16-MICB complex elucidates select binding of a viral immunoevasin to diverse NKG2D ligands.
    Müller S; Zocher G; Steinle A; Stehle T
    PLoS Pathog; 2010 Jan; 6(1):e1000723. PubMed ID: 20090832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-Throughput
    Klussmeier A; Massalski C; Putke K; Schäfer G; Sauter J; Schefzyk D; Pruschke J; Hofmann J; Fürst D; Carapito R; Bahram S; Schmidt AH; Lange V
    Front Immunol; 2020; 11():314. PubMed ID: 32153595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA.
    Kloess S; Huenecke S; Piechulek D; Esser R; Koch J; Brehm C; Soerensen J; Gardlowski T; Brinkmann A; Bader P; Passweg J; Klingebiel T; Schwabe D; Koehl U
    Eur J Immunol; 2010 Nov; 40(11):3255-67. PubMed ID: 21061445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD.
    Carapito R; Jung N; Kwemou M; Untrau M; Michel S; Pichot A; Giacometti G; Macquin C; Ilias W; Morlon A; Kotova I; Apostolova P; Schmitt-Graeff A; Cesbron A; Gagne K; Oudshoorn M; van der Holt B; Labalette M; Spierings E; Picard C; Loiseau P; Tamouza R; Toubert A; Parissiadis A; Dubois V; Lafarge X; Maumy-Bertrand M; Bertrand F; Vago L; Ciceri F; Paillard C; Querol S; Sierra J; Fleischhauer K; Nagler A; Labopin M; Inoko H; von dem Borne PA; Kuball J; Ota M; Katsuyama Y; Michallet M; Lioure B; Peffault de Latour R; Blaise D; Cornelissen JJ; Yakoub-Agha I; Claas F; Moreau P; Milpied N; Charron D; Mohty M; Zeiser R; Socié G; Bahram S
    Blood; 2016 Oct; 128(15):1979-1986. PubMed ID: 27549307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vesicular stomatitis virus infection promotes immune evasion by preventing NKG2D-ligand surface expression.
    Jensen H; Andresen L; Nielsen J; Christensen JP; Skov S
    PLoS One; 2011; 6(8):e23023. PubMed ID: 21857986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA.
    Holdenrieder S; Stieber P; Peterfi A; Nagel D; Steinle A; Salih HR
    Cancer Immunol Immunother; 2006 Dec; 55(12):1584-9. PubMed ID: 16636811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Down-regulation of the human major histocompatibility complex class I chain-related gene A (MICA) and its receptor is mediated by microRNA-146b-5p and is a potential mechanism of immunoediting in papillary thyroid carcinoma.
    Al-Abdallah A; Jahanbani I; Mehdawi H; Ali RH; Al-Brahim N; Mojiminiyi O; Junaid TA
    Exp Mol Pathol; 2020 Apr; 113():104379. PubMed ID: 31935378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.
    Raneros AB; Minguela A; Rodriguez RM; Colado E; Bernal T; Anguita E; Mogorron AV; Gil AC; Vidal-Castiñeira JR; Márquez-Kisinousky L; Bulnes PD; Marin AM; Garay MCG; Suarez-Alvarez B; Lopez-Larrea C
    Oncotarget; 2017 May; 8(19):31959-31976. PubMed ID: 28404876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.
    Raffaghello L; Prigione I; Airoldi I; Camoriano M; Levreri I; Gambini C; Pende D; Steinle A; Ferrone S; Pistoia V
    Neoplasia; 2004; 6(5):558-68. PubMed ID: 15548365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. STAT3 inhibition by STA21 increases cell surface expression of MICB and the release of soluble MICB by gastric adenocarcinoma cells.
    Garrido-Tapia M; Hernández CJ; Ascui G; Kramm K; Morales M; Ga Rate V; Zúñiga R; Bustamante M; Aguillón JC; Catala N D; Ribeiro CH; Molina MAC
    Immunobiology; 2017 Nov; 222(11):1043-1051. PubMed ID: 28578917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. KLF4-mediated upregulation of the NKG2D ligand MICA in acute myeloid leukemia: a novel therapeutic target identified by enChIP.
    Alkhayer R; Ponath V; Frech M; Adhikary T; Graumann J; Neubauer A; von Strandmann EP
    Cell Commun Signal; 2023 May; 21(1):94. PubMed ID: 37143070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetics, genomics, and evolutionary biology of NKG2D ligands.
    Carapito R; Bahram S
    Immunol Rev; 2015 Sep; 267(1):88-116. PubMed ID: 26284473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cervical cancer cell lines expressing NKG2D-ligands are able to down-modulate the NKG2D receptor on NKL cells with functional implications.
    Jimenez-Perez MI; Jave-Suarez LF; Ortiz-Lazareno PC; Bravo-Cuellar A; Gonzalez-Ramella O; Aguilar-Lemarroy A; Hernandez-Flores G; Pereira-Suarez AL; Daneri-Navarro A; del Toro-Arreola S
    BMC Immunol; 2012 Feb; 13():7. PubMed ID: 22316211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Varicella-Zoster Virus and Herpes Simplex Virus 1 Differentially Modulate NKG2D Ligand Expression during Productive Infection.
    Campbell TM; McSharry BP; Steain M; Slobedman B; Abendroth A
    J Virol; 2015 Aug; 89(15):7932-43. PubMed ID: 25995251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NKG2D discriminates diverse ligands through selectively mechano-regulated ligand conformational changes.
    Fan J; Shi J; Zhang Y; Liu J; An C; Zhu H; Wu P; Hu W; Qin R; Yao D; Shou X; Xu Y; Tong Z; Wen X; Xu J; Zhang J; Fang W; Lou J; Yin W; Chen W
    EMBO J; 2022 Dec; 41(2):e107739. PubMed ID: 34913508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.